/
AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.
$215.40
+$2.47 (+1.16%)
Price from 2 days ago
Margins and capital returns are both well above average: 24.65% operating margin, ROIC at 16.74%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 8.6%, steady but not accelerating.
At 106x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
106.1x earnings, 19.1x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$62.82B
▲ +8.6% YoY
Net Income (TTM)
$3.63B
▼ -1.2% YoY
Op. Margin
24.41%
▲ +8.4pp YoY
ROIC
18.17%
▲ +7.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$19.98B
Op. Cash Flow (TTM)
$21.22B
▲ +1.2% YoY
Net Debt
$63.47B
Cash & Equiv.
$9.39B
5Y CAGR: +6.0%
5Y CAGR: +1.2%
Continue Research